- At the Citi Annual Biotech Conference on September 8, 2016 at
8:00AM ETin Boston, Joshua H. Bilenker, M.D., chief executive officer, will be participating in a panel discussion entitled, “Developing Cancer Therapeutics in 2016”
- At the
Morgan Stanley Global Healthcare Conferenceon September 14, 2016 at 2:10PM ETin New York City, Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview
Live webcasts of the panel and presentation will be available at http://ir.loxooncology.com/.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Chief Business Officer
Pure Communications, Inc.